In order to validate the impact of tumour immune phenotypes and the overall immune cell infiltrate, prospective clinical trials with comprehensive biomarker analysis beyond PD-L1 expression and therapeutic data of larger and multicentre cohorts of pure squamous cell carcinomas and mixed urothelial carcinomas with squamous differentiation are needed. This evidence concerns the gene CD274 and neoplasm.